12 Results for "

opioid-induced constipation

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "opioid-induced constipation" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-19627A
CAS No.: 1345728-04-2
Synonyms: S-297995 tosylate
Target:  

Opioid Receptor

Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-A0118A
CAS No.: 1354744-91-4
Synonyms: NKTR-118 oxalate; AZ-13337019 oxalate
Target:  

Opioid Receptor

Research Areas:  

Metabolic Disease

Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .
loading...
    loading...
Cat. No.: HY-19627
CAS No.: 916072-89-4
Synonyms: S-297995
Target:  

Opioid Receptor

Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
loading...
    loading...
Cat. No.: HY-113254
CAS No.: 363-23-5
Purity:  96.7%
Research Areas:  

Endocrinology

13,14-Dihydro-15-keto-PGE2 participates in Bifidobacterium animalis F1-7 to alleviate opioid-induced constipation by 5-HT pathway .
loading...
    loading...
Cat. No.: HY-B0680
CAS No.: 333963-40-9
Synonyms: RU-0211 (hemiketal); SPI-0211 (hemiketal)
Target:  

Chloride Channel

Research Areas:  

Others Cancer

Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .
loading...
    loading...
Cat. No.: HY-144606
CAS No.: 2767446-03-5
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an Ki value of 0.58 nM and an EC50 of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .
loading...
    loading...
Cat. No.: HY-A0118
CAS No.: 854601-70-0
Synonyms: NKTR-118; AZ-13337019
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease Cancer

Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .
loading...
    loading...
Cat. No.: HY-16765
CAS No.: 949904-48-7
Synonyms: TD-1211
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
loading...
    loading...
Cat. No.: HY-A0118AS
Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
loading...
    loading...
Cat. No.: HY-A0118S
Synonyms: NKTR-118-13C,d3; AZ-13337019-13C,d3
Naloxegol- 13C,d3 (NKTR-118- 13C,d3) is 13C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
loading...
    loading...
Cat. No.: HY-A0118S1
Synonyms: NKTR-118-13C,d2; AZ-13337019-13C,d2
Naloxegol- 13C,d2 (NKTR-118- 13C,d2) is 13C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
loading...
    loading...
Cat. No.: HY-16765A
CAS No.: 949904-50-1
Synonyms: TD-1211 sulfate
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
loading...
    loading...
  • 1